These compelling findings establish that LiSmore efficiently promotes the activation of antigen-presenting cells and enhances cross-presentation of tumor antigens, effectively priming effector CD8+ T cells for targeted tumor killing in a light-dependent manner. Here, CD8A is linked to neoplasm.